1. Home
  2. KPTI vs MRT Comparison

KPTI vs MRT Comparison

Compare KPTI & MRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KPTI
  • MRT
  • Stock Information
  • Founded
  • KPTI 2008
  • MRT 2018
  • Country
  • KPTI United States
  • MRT Turkey
  • Employees
  • KPTI N/A
  • MRT N/A
  • Industry
  • KPTI Biotechnology: Pharmaceutical Preparations
  • MRT Rental/Leasing Companies
  • Sector
  • KPTI Health Care
  • MRT Consumer Discretionary
  • Exchange
  • KPTI Nasdaq
  • MRT Nasdaq
  • Market Cap
  • KPTI 121.2M
  • MRT 117.0M
  • IPO Year
  • KPTI 2013
  • MRT N/A
  • Fundamental
  • Price
  • KPTI $0.87
  • MRT $2.00
  • Analyst Decision
  • KPTI Strong Buy
  • MRT Buy
  • Analyst Count
  • KPTI 4
  • MRT 1
  • Target Price
  • KPTI $5.00
  • MRT $0.90
  • AVG Volume (30 Days)
  • KPTI 873.0K
  • MRT 49.3K
  • Earning Date
  • KPTI 10-31-2024
  • MRT 01-01-0001
  • Dividend Yield
  • KPTI N/A
  • MRT N/A
  • EPS Growth
  • KPTI N/A
  • MRT N/A
  • EPS
  • KPTI N/A
  • MRT N/A
  • Revenue
  • KPTI $145,668,000.00
  • MRT $18,953,502.00
  • Revenue This Year
  • KPTI $6.41
  • MRT N/A
  • Revenue Next Year
  • KPTI $11.85
  • MRT N/A
  • P/E Ratio
  • KPTI N/A
  • MRT N/A
  • Revenue Growth
  • KPTI N/A
  • MRT N/A
  • 52 Week Low
  • KPTI $0.62
  • MRT $0.44
  • 52 Week High
  • KPTI $1.95
  • MRT $2.73
  • Technical
  • Relative Strength Index (RSI)
  • KPTI 60.31
  • MRT 50.45
  • Support Level
  • KPTI $0.71
  • MRT $1.77
  • Resistance Level
  • KPTI $0.94
  • MRT $2.10
  • Average True Range (ATR)
  • KPTI 0.07
  • MRT 0.12
  • MACD
  • KPTI 0.02
  • MRT -0.01
  • Stochastic Oscillator
  • KPTI 72.24
  • MRT 64.82

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

About MRT Marti Technologies Inc.

Marti Technologies Inc is a mobility app, operating a fleet of over 48,000 e-mopeds, e-bikes, and e-scooters, serviced by proprietary software systems and IoT infrastructure.

Share on Social Networks: